Overcoming the current deadlock in antibiotic research.
Antibiotic-resistant bacteria are on the rise, making it harder to treat bacterial infections. The situation is aggravated by the shrinking of the antibiotic development pipeline. To finance urgently needed incentives for antibiotic research, creative financing solutions are needed. Public-private partnerships (PPPs) are a successful model for moving forward.
Institute for Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany. Electronic address: till.schaeberle@uni-bonn.de.
Till F
TF
Schäberle
Federal Ministry for Economic Cooperation and Development, Dahlmannstr. 4, 53114 Bonn, Germany.
Ingrid M
IM
Hack
D000900:Anti-Bacterial Agents / Q000191:economics* / Q000302:isolation & purification* / Q000494:pharmacology; D001424:Bacterial Infections / Q000188:drug therapy; D002202:Capital Financing; D055808:Drug Discovery / Q000191:economics / Q000379:methods / Q000639:trends; D024881:Drug Resistance, Bacterial; D006801:Humans; D055818:Public-Private Sector Partnerships
D000900:Anti-Bacterial Agents
antibiotic resistance; public health; public–private partnership (PPP)